In-Depth Examination of Segments, Industry Developments, and Key Players in the Rare Kidney Diseases Market

The rare kidney diseases market is poised for significant growth over the coming years, driven by advancements in treatment options and increasing research efforts. This expanding field reflects the growing focus on developing innovative therapies and improving patient outcomes for these uncommon but impactful conditions.

Rare Kidney Diseases Market Expected to Reach $4.88 Billion by 2030
The market for rare kidney diseases is anticipated to grow rapidly, reaching a valuation of $4.88 billion by 2030. This expansion is projected to occur at a compound annual growth rate (CAGR) of 10.2%. Key factors behind this growth include breakthroughs in genomics-based drug discovery, a rise in approvals for orphan drugs, increased funding dedicated to rare disease research, the broader adoption of personalized medicine, and the development of complement and immune-targeted therapies. Among the notable trends are heightened attention to targeted treatments for rare renal disorders, growing clinical trial activities focused on orphan kidney drugs, wider use of biologics for immune-mediated kidney diseases, advances in companion diagnostics that enable earlier disease detection, and stronger regulatory incentives encouraging rare disease drug development.

Download a free sample of the rare kidney diseases market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Organizations Driving Progress in the Rare Kidney Diseases Market
Several prominent companies are at the forefront of the rare kidney diseases market, including Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, and Reata Pharmaceuticals Inc.

In a notable deal in February 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical firm, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition is part of AstraZeneca's strategy to strengthen its portfolio in chronic kidney diseases and uncontrolled hypertension. CinCor Pharma, also based in the US, is a clinical-stage biopharmaceutical company that develops treatments specifically for rare kidney diseases.

View the full rare kidney diseases market report:
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Focus on Non-Immunosuppressive Therapies in Rare Kidney Disease Treatment
A key trend among market players is the development of non-immunosuppressive therapies aimed at treating rare kidney conditions. Unlike conventional treatments, these therapies offer solutions for patients with progressive kidney disease who do not respond well to typical immunosuppressive drugs. For example, in February 2023, Travere Therapeutics, based in the US, introduced sparsentan, marketed as Filspari. This drug is the first non-immunosuppressive therapy approved to treat primary immunoglobulin A nephropathy (IgAN).

How Filspari Stands Out in Rare Kidney Disease Management
Filspari operates through a unique mechanism by blocking both angiotensin and endothelin receptors. This differentiates it from angiotensin-targeting drugs like ACE inhibitors and angiotensin receptor blockers (ARBs), which are commonly prescribed for hypertension and have been repurposed to manage IgAN due to their kidney blood pressure-lowering effects. This novel mode of action offers a promising alternative for IgAN patients, potentially improving treatment outcomes.

Detailed Segment Analysis Within the Rare Kidney Diseases Market
The rare kidney diseases market is segmented into various categories to reflect different aspects of the treatment landscape:

1) Target Indications:
- IgA Nephropathy
- Lupus Nephritis
- Focal Segmental Glomerular Sclerosis (FSGS)
- Membranous Nephropathy
- C3 Glomerulopathy
- Other Target Indications

2) Type of Molecule:
- Small Molecules
- Biologics

3) Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- Other Routes

Subcategories provide further granularity by treatment type for specific indications:

- IgA Nephropathy: Immunosuppressive Therapy, Supportive Care, and Symptomatic Management
- Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics
- FSGS: Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents
- Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies
- C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies
- Other Indications: Includes Alport Syndrome, Thin Basement Membrane Nephropathy, and other rare kidney disorders

This detailed segmentation highlights the diversity of treatment approaches and the specialized focus within the rare kidney disease market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.